Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152


CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.

Gille A, Easton R, D'Andrea D, Wright SD, Shear CL.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2106-14. doi: 10.1161/ATVBAHA.114.303720. Epub 2014 Jun 26.


Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.

Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, Leis A, Wright SD.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11. doi: 10.1161/ATVBAHA.113.301981. Epub 2013 Jul 18.


A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.

Easton R, Gille A, D'Andrea D, Davis R, Wright SD, Shear C.

J Clin Pharmacol. 2014 Mar;54(3):301-10. doi: 10.1002/jcph.194. Epub 2013 Oct 22.


Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.

Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH.

J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.


Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Thérond P, Chapman MJ, Kontush A, Wright SD.

Circ Res. 2016 Sep 2;119(6):751-63. doi: 10.1161/CIRCRESAHA.116.308685. Epub 2016 Jul 19.


CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.

Gille A, D'Andrea D, Tortorici MA, Hartel G, Wright SD.

Arterioscler Thromb Vasc Biol. 2018 Feb 8. pii: ATVBAHA.118.310538. doi: 10.1161/ATVBAHA.118.310538. [Epub ahead of print]


High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.

Kempen HJ, Asztalos BF, Moerland M, Jeyarajah E, Otvos J, Kallend DG, Bellibas SE, Wijngaard PL.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):736-42. doi: 10.1161/ATVBAHA.115.307052. Epub 2016 Feb 25.


Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA.

Circulation. 2016 Dec 13;134(24):1918-1930. Epub 2016 Nov 15.


Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.

Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K.

Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2246-53. doi: 10.1161/ATVBAHA.114.303715. Epub 2014 Aug 7.


HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Borja MS, Ng KF, Irwin A, Hong J, Wu X, Isquith D, Zhao XQ, Prazen B, Gildengorin V, Oda MN, Vaisar T.

J Lipid Res. 2015 Oct;56(10):2002-9. doi: 10.1194/jlr.M059865. Epub 2015 Aug 7.


HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.

Tardy C, Goffinet M, Boubekeur N, Cholez G, Ackermann R, Sy G, Keyserling C, Lalwani N, Paolini JF, Dasseux JL, Barbaras R, Baron R.

PLoS One. 2015 Sep 3;10(9):e0137584. doi: 10.1371/journal.pone.0137584. eCollection 2015.


Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.

Cukier AMO, Therond P, Didichenko SA, Guillas I, Chapman MJ, Wright SD, Kontush A.

Biochim Biophys Acta. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.


Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.

Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, Oda MN, Zhao XQ, Heinecke JW.

Circ Res. 2014 May 23;114(11):1733-42. doi: 10.1161/CIRCRESAHA.114.303454. Epub 2014 Mar 19.


Increased cholesterol efflux capacity in metabolic syndrome: Relation with qualitative alterations in HDL and LCAT.

Lucero D, Sviridov D, Freeman L, López GI, Fassio E, Remaley AT, Schreier L.

Atherosclerosis. 2015 Sep;242(1):236-42. doi: 10.1016/j.atherosclerosis.2015.07.019. Epub 2015 Jul 10. Erratum in: Atherosclerosis. 2015 Nov;243(1):59. Svidirov, Denis [corrected to Sviridov, Denis].


Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.

Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomäki A, Miettinen TA, Kontula K.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3021-32.


Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans.

Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE.

J Lipid Res. 2001 Oct;42(10):1586-93.


Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein.

Hoang A, Drew BG, Low H, Remaley AT, Nestel P, Kingwell BA, Sviridov D.

Eur Heart J. 2012 Mar;33(5):657-65. doi: 10.1093/eurheartj/ehr103. Epub 2011 Apr 15.


Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Hewing B, Parathath S, Barrett T, Chung WK, Astudillo YM, Hamada T, Ramkhelawon B, Tallant TC, Yusufishaq MS, Didonato JA, Huang Y, Buffa J, Berisha SZ, Smith JD, Hazen SL, Fisher EA.

Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):779-89. doi: 10.1161/ATVBAHA.113.303044. Epub 2014 Jan 9.


Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.

Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ.

Circ Res. 2005 Oct 14;97(8):763-71. Epub 2005 Sep 8.

Supplemental Content

Support Center